LIB003
Phase 3 study in homozygous FH
Trial Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH ClinicalTrials.gov Identifier: NCT04034485 Aim To compare the safety, tolerability and low-density lipoprotein cholesterol (LDL-C) response after 24 weeks of 4-weekly subcutaneous (SC) dosing of LIB003 300 mg with 4-weekly…
read more »
Open-label extension study
Trial Open-Label Extension to Evaluate the Longer-Term Efficacy and Safety of LIB003 ClinicalTrials.gov Identifier: NCT03847974 Aim To assess the longer-term safety, tolerability, and low-density lipoprotein cholesterol (LDL-C) lowering efficacy of LIB003 with subcutaneous (SC) dosing every 4 weeks Study Design Open-label; all patients were allocated…
read more »
Phase 2 dose-ranging study
Trial Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction ClinicalTrials.gov Identifier: NCT03549260 Aim To assess the low-density lipoprotein cholesterol (LDL-C) lowering efficacy of different doses of LIB003 administered every 4 weeks in subjects on stable statin…
read more »
